LearnGlossaryMarketStocksSuperinvestorsSign in

RCKT

Rocket Pharmaceuticals, Inc.

Healthcare · $283M market cap

Verdict

We can't put a fair value on RCKT right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.

Business quality

0 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth—?
Equity per share growth-9.3% a year✗
Sales growth—?
Free cash flow growth—?
Return on invested capital-60.3%✗

Follow RCKT

Track it on your watchlist and see the full analysis. Free.

Create a free account

Superinvestors

1 of the investors we track holds RCKT. In Q1 2026, 1 added. Who we track

Lee Ainslie

Maverick Capital · as of Q2 2026

$13.4M

3,923,963 shares

Moves in Q1 2026

Added: Lee Ainslie

About Rocket Pharmaceuticals, Inc.

Rocket Pharmaceuticals, Inc., operating alongside its affiliates, is an innovative biotechnology enterprise dedicated to pioneering gene therapies for rare and severely debilitating diseases. The company's active clinical pipeline features multiple promising programs. It is currently progressing three ex vivo lentiviral vector therapies aimed at specific genetic conditions: Fanconi anemia, characterized by a bone…

Biotechnology

Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works